Repros Therapeutics Inc. (RPRX) Initiates Two Head To Head Studies Of Androxal® Versus The Leading Topical Testosterone Gel
1/8/2014 9:08:16 AM
THE WOODLANDS, Texas, Jan. 8, 2014 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced it has initiated two clinical studies comparing Androxal to the leading US testosterone replacement therapy. Investigational Review Board approval has already been obtained for several of the study sites and an investigator meeting and shipment of drug is scheduled for next week. Several sites have begun pre-screening subjects. The FDA has previously indicated that head to head studies could be conducted against approved testosterone products to establish claims for labeling purposes with the proviso that Androxal must show superiority to the testosterone product for any specific claims to be made.
Help employers find you! Check out all the jobs and post your resume.
comments powered by